#AANAM – Blacks, Whites Respond Differently to B-cell Targeting Therapies

#AANAM – Blacks, Whites Respond Differently to B-cell Targeting Therapies

292263

#AANAM – Blacks, Whites Respond Differently to B-cell Targeting Therapies

Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Common B-cell depleting therapies, such as rituximab and Ocrevus (ocrelizumab), may result in shorter duration B-cell depleting effects in African American patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) than in white patients, a study suggests. “While previous research has shown that this type…

You must be logged in to read/download the full post.